Home
Search
Study Topics
Glossary
|
|
|
|
|
Sponsored by: |
Columbia University |
---|---|
Information provided by: | Columbia University |
ClinicalTrials.gov Identifier: | NCT00670410 |
HYPOTHESIS: The combination of high dose induction chemotherapy, followed by consolidation with myeloablative therapy (MAT) and autologous stem cell transplant (AutoSCT), followed by immunotherapy with non-myeloablative therapy (NAT) and allogeneic stem cell transplant (AlloSCT) from either a related donor or umbilical cord donor, will be well tolerated, and provide information to develop future randomized trials testing the role of NAT/AlloSCT in patients with high-risk neuroblastoma after undergoing MAT/AutoSCT.
Condition | Intervention | Phase |
---|---|---|
Neuroblastoma |
Procedure: Related donor stem cell transplant Procedure: unrelated cord blood transplant |
Phase I |
Study Type: | Interventional |
Study Design: | Treatment, Non-Randomized, Open Label, Uncontrolled, Single Group Assignment, Safety/Efficacy Study |
Official Title: | A Pilot Study of Sequential Autologous Stem Cell Transplantation and Immunotherapy With Reduced Intensity Allogeneic Stem Cell Transplant for High Risk Neuroblastoma |
Estimated Enrollment: | 36 |
Study Start Date: | December 2002 |
Estimated Study Completion Date: | December 2011 |
Estimated Primary Completion Date: | January 2011 (Final data collection date for primary outcome measure) |
Arms | Assigned Interventions |
---|---|
Arm A: Experimental
Related Donor
|
Procedure: Related donor stem cell transplant
Patients with a related donor will get reduced intensity transplant conditioning with busulfan and fludarabine.
|
Arm B: Experimental
Cord Blood donor
|
Procedure: unrelated cord blood transplant
patients with an matched unrelated cord blood donor will get reduced intensity conditioning with busulfan, fludarabine, and ATG.
|
Despite the modest advances made over the past two decades with the addition of more intensive chemotherapy and high dose myeloablative therapy with allogeneic or autologous bone marrow transplantation, children with high-risk neuroblastoma continue to have an unsatisfactory long-term survival. The current survival for a child > 1 year of age at diagnosis with stage 4 neuroblastoma is only 20-35% 1,7. The overall treatment plan for high-risk patients with neuroblastoma will be: Induction Therapy Intensive induction chemotherapy with the cardioprotectant dexrazoxane (Zinecard), vincristine, doxorubicin (Adriamycin), and cyclophosphamide (ZVAC), alternating with cisplatin and etoposide (CiE). Patients who receive induction chemotherapy on an alternate protocol and achieve a CR, VGPR, or PR will also be eligible for entry to receive consolidation therapy and AlloSCT immunotherapy after discussion and approval of the Principal Investigators ). Consolidation Therapy with AutoSCT Consolidation therapy with a myeloablative preparative regimen of carboplatin, thiotepa, and topotecan (CaTT) followed by AutoSCT with PBSCs (CD34+ selection optional). Immunotherapy with Non-myeloablative AlloSCT Immunotherapy with a non-myeloablative preparative regimen of busulfan and fludarabine followed by AlloSCT with either: (Arm A) a related donor (5/6 or 6/6 HLA matched); or (Arm B) an umbilical cord blood donor (unrelated 4/6, 5/6, or 6/6 HLA matched, or related 3/6, 4/6, 5/6, or 6/6 HLA matched). Patients with an umbilical cord blood donor will also receive Thymoglobulin (ATG-rabbit) during the preparative regimen. GVHD prophylaxis will consist of Tacrolimus and mycophenolate mofetil (MMF). Maintenance Therapy Patients with a related donor who have persistent disease detected prior to NAT/AlloSCT will be assigned to Arm A1 and will receive two courses of DLI, followed by cis-RA for 6 cycles. Patients with a related donor with no persistent disease detected prior to NAT/AlloSCT will be assigned to Arm A2 and receive cis-RA for 6 cycles.
Patients with an umbilical cord blood donor will receive cis-RA for 6 cycles. Radiation Therapy Due to the potential risk of increased GVHD following radiation therapy, local radiation therapy to the primary tumor site (21 Gy) and metastatic sites, will be given after NAT/AlloSCT for patients on Arm A2 and Arm B, and prior to cis-RA therapy. Radiation therapy will be given following DLI in Arm A1, and prior to cis-RA therapy.
Ages Eligible for Study: | up to 30 Years |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Patients with newly diagnosed neuroblastoma and age > 547 days with the following:
Patients with newly diagnosed neuroblastoma and age < 365 days with the following:
Patients with newly diagnosed Neuroblastoma and age 365 - <547 days with the following:
Exclusion Criteria:
United States, New York | |
Columbia Presbyterian Medical Center, Morgan Stanley Children's Hospital New York Presbyterian | |
New York, New York, United States, 10032 |
Study Chair: | Darrell Yamashiro, MD | Columbia University |
Responsible Party: | Columbia University ( John Ennever, MD, PhD/Director, Regulatory Knowledge and Support Resource ) |
Study ID Numbers: | CHNY-01-502, AAAA7937 |
Study First Received: | April 29, 2008 |
Last Updated: | May 14, 2009 |
ClinicalTrials.gov Identifier: | NCT00670410 History of Changes |
Health Authority: | United States: Institutional Review Board |
Neuroblastoma Autologous Transplant Allogeneic Transplant Immunotherapy |
Neuroectodermal Tumors Neuroectodermal Tumors, Primitive Busulfan Neoplasms, Germ Cell and Embryonal Neuroepithelioma |
Fludarabine Fludarabine monophosphate Neuroectodermal Tumors, Primitive, Peripheral Neuroblastoma Neoplasms, Glandular and Epithelial |
Neuroectodermal Tumors Neoplasms Neoplasms by Histologic Type Neuroectodermal Tumors, Primitive Neoplasms, Germ Cell and Embryonal |
Neoplasms, Nerve Tissue Neoplasms, Neuroepithelial Neuroectodermal Tumors, Primitive, Peripheral Neuroblastoma Neoplasms, Glandular and Epithelial |